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Arterial Diseases, in Collaboration With the European Society for Vascular
Surgery (ESVS)The Collaboration of the European Society for Vascular
Surgery (ESVS) and the European Society of Cardiology (ESC)
in new Guidelines for Peripheral Arterial Diseases (PAD) is
new and very welcome.1 The ESVS Carotid and Vertebral
Guidelines have just been published2 and, in this issue, the
ESC & ESVS PAD Guidelines will highlight the evidence and
views of this multidisciplinary collaboration of specialists
in vascular disease in Europe today. As we stress here, these
Guidelines emphasise the importance of the multidisci-
plinary “Vascular Team” in holistic management of these
patients, including comprehensive cardiovascular preventive
measures and integrated cardiac risk management of PAD
patients.
Recommendations are provided in both Guideline docu-
ments and graded according to the ESC system. These
include level of evidence (A, B, C) and the class of recom-
mendation (I, II, III). Class I indicates general agreement on
what is formally indicated, in Class IIa there is conﬂicting
evidence or divergence of opinion, whereas, for Class IIb,
usefulness is less well established and in Class III there is
general agreement that a given treatment is not useful or
may even be harmful. This system is now almost identical to
the American Heart Association (AHA) grading system,
facilitating future comparisons of Guideline recommenda-
tions between the USA and Europe.3
The ESVS Carotid and Vertebral Guidelines cover 64
pages and 475 references, with an in-depth focus on all
issues regarding management of cerebrovascular disease,
while the new ESC & ESVS PAD Guideline had the challenge
to produce a single document of 50 pages (and 420 refer-
ences) covering a much wider range of topics, including
some of particular interest to cardiologists, but of deﬁnite
importance to surgeons, such as the cardiac conditions
other than coronary artery disease in patients with PAD (i.e.
heart failure, atrial ﬁbrillation, valvular heart disease and
vascular access). Both Guidelines emphasise the importance
of investigating multisite artery disease. Importantly, in the
new ESC & ESVS document, PAD encompasses all the pe-
ripheral territories, covering carotid and vertebral, mesen-
teric artery disease, renal artery disease, as well as upper
and lower extremity artery diseases.1078-5884/ 2018 European Society for Vascular Surgery. Published by
Elsevier Ltd. All rights reserved.
https://doi.org/10.1016/j.ejvs.2018.03.004The ESC & ESVS Guidelines address gaps in evidence as well
as giving ‘To do and not to do’ messages, which may be of
particular interest to non-vascular specialists or general prac-
titioners. Where ESC covers antithrombotic drugs for a wide
range of PAD, ESVS covers drug treatments for carotid and
vertebral disease. Both Guidelines address the evidence for
management of concurrent coronary and carotid disease, for
carotid disease with major non-cardiac surgery and for occlu-
sive disease of proximal common carotid and innominate ar-
teries. The ESVS document takes more space to tackle newer
issues which have become topical, such as the relationship (or
not) of carotid disease to dementia, opportunities for future
trials and, of course, the timing of carotid surgery, surgical
techniques and complications that may occur.
THE NEW ESC & ESVS PAD GUIDELINES eWHAT IS REALLY
NEW?
This document replaces the ESC 2011 Guidelines on PAD, with
some signiﬁcant differences. There is downgrading of the
previous indications for revascularization of asymptomatic
carotid stenosis and inclusion of data indicating that revascu-
larisation of carotid stenosis for CABG is mostly unnecessary;
other differences include the ‘how todo it and inwhom’boxes,
such as for PAD detection, the useful ﬁgures on antiplatelet
therapy for carotid disease and PAD, a helpful section onwhen
oral anticoagulation is indicated, a reminder that using
treadmill walking tests for PAD is valuable, the ‘WIFI’ classiﬁ-
cation for assessing amputation risk and an update of the co-
incidence of other vascular diseases for each disease terri-
tory, an example being ‘39%e61% of patients with more than
70% carotid stenosis have CAD’.
WHO WILL READ EACH (OR INDEED BOTH)?
The cardiologist and vascular physician are well catered for
in these new ESC & ESVS PAD Guidelines. The Surgeon will
ﬁnd it refreshing to see the evidence from their point of
view, and can appreciate that, when cardiac disease is
prevalent, close multidisciplinary collaboration is required
to improve patient outcome. The neurologist and stroke
interventionalist just might read both, since the European
Stroke Organisation (ESO) endorses these new ESC/ESVS
Guidelines. However, some interventionalists may be un-
certain about their place in this new world e for example,
should more cardiologists and surgeons provide acute
endovascular interventions in PAD, or will they be con-
strained by local training requirements? Finally, this is a
302 Editorialunique document summarizing the evidence and the
optimal management for all peripheral territories and from
this standpoint, it should deﬁnitely interest any training
physician or surgeon who wants to have all the information
in one place, written by experts from both societies.
As a general rule for any ESC Guidelines document, this PAD
Guidelines document has been reviewed (at least for Class I
and III recommendations) byeveryNational Cardiology Society
prior to approval, but practice in every European Country is
differente this has not been addressed, as Guidelines will not
assess problems of European National Healthcare provision,
which may be centrally- or Insurance-funded, driven by gen-
eral practice budgets or by hospital proﬁt. The ability of all
European countries to provide the services described in these
new Guidelines is uncertain. This should be our next aim in a
new ESC & ESVS Collaboration e to provide standards for the
care of patients with vascular disease in Europe, taking into
account the regional differences in different countries. The
ESVS and the ESC will join their efforts for a new joint
endeavour e one aiming to improve delivery of the care rec-
ommended in these excellent Guidelines.
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